
Longeveron Inc (NASDAQ:LGVN) has announced a Cooperative Research and Development Agreement (CRADA) with the United States Department of Veterans Affairs (VA) to add Miami VA clinical site to its ongoing Phase 2 Alzheimer’s Disease (AD) trial.
Why It Matters: This marks the third separate CRADA agreement between the VA and Longeveron, including an Aging Frailty study and an ongoing study on COVID-19.